Show newer

RT @UMCGlobalSafety: 💡We're pleased to launch a new communications resource! The PV Cycle explores each stage of the medicines safety cycle via the eyes of a diabetic patient and highlights the importance of reporting side effects.

Follow Lisa's journey 👉 ow.ly/EoZ950LOJE4

🐦🔗: nitter.eu/EMA_News/status/1597

RT @WHO: Following consultations, WHO will begin using a new term for “” disease: ''.
Both names will be used simultaneously for one year while 'monkeypox' is phased out who.int/news/item/28-11-2022-w

🐦🔗: nitter.eu/EMA_News/status/1597

Save the date!

EMA and Heads of Medicines Agencies are hosting the 3rd annual forum to foster collaboration and engage stakeholders on 1 December 2022.

The event will be available to watch live 📺⬇ :
ema.europa.eu/en/events/eu-big

🐦🔗: nitter.eu/EMA_News/status/1596

Save the date!

EMA and Heads of Medicines Agencies are hosting the 3rd annual forum to foster collaboration and engage stakeholders on 1 December 2022.

The event will be available to watch live 📺⬇ :
ema.europa.eu/en/events/eu-big

🐦🔗: nitter.eu/EMA_News/status/1596

Are you a sponsor? As of 🗓️31 January 2023, you will have to use the Clinical Trials Information System and follow the same process to apply for the authorisation of a clinical trial in the .
Learn more from the video 👇

🐦🔗: nitter.eu/EMA_News/status/1596

RT @EAAD_EU: myth-busting time!
“I am in good health and rarely sick, I cannot become resistant to antibiotics”.

THIS IS (DOUBLE) FALSE!

Why? Watch our video and learn more!

Let's prevent together!

antibiotic.ecdc.europa.eu/en/e

🐦🔗: nitter.eu/EMA_News/status/1595

RT @EC_HERA: On 2⃣2⃣ and 2⃣3⃣ November, HERA & @EUScienceInnov organised a multidisciplinary workshop on broad-spectrum antivirals to discuss an end-to-end approach for the development, availability and access of broad-spectrum antivirals to fight future pandemics.

Curious to learn more? 👇

🐦🔗: nitter.eu/EMA_News/status/1595

EMA is open to all developers of 💊💊 for the treatment or prevention of life-threatening bacterial infections. We urge companies to focus more on research and development of antimicrobials.

🐦🔗: nitter.eu/EMA_News/status/1594

RT @ECDC_EU: Respiratory syncytial virus () is a seasonal virus that recurs throughout the year in Europe with peaks mainly during the autumn, winter, and spring months (October to April), and is a leading cause of acute lower respiratory tract infections in infants and young children.

🐦🔗: nitter.eu/EMA_News/status/1595

EMA has selected the first data partners to collaborate with ®.

This will help generate that can support scientific evaluations and regulatory decision making on medicines.

List of data partners available on our website: ema.europa.eu/en/news/darwin-e

🐦🔗: nitter.eu/EMA_News/status/1595

Today from 09:30 CET!

EMA is organising the 2nd annual forum on in veterinary medicines regulation to foster collaboration and engage stakeholders.

Tune in and follow our live until 17:00

Watch live 📺⬇
ema.europa.eu/en/events/second

🐦🔗: nitter.eu/EMA_News/status/1595

‼️ Only together can we prevent harm caused by .
Europe is on the right track - let’s stay there. We need to spread knowledge, change behaviours and take urgent action to fight .

🐦🔗: nitter.eu/EMA_News/status/1594

EMA has established a new group of experts to supports medicine , for the benefit of in the 🇪🇺.

It fosters innovative approaches for the development, manufacture, and quality control of medicines. 💊

Read more: ema.europa.eu/en/news/new-qual

🐦🔗: nitter.eu/EMA_News/status/1595

Show older
Mastodon

A Mastodon forum for the discussion of European Union matters. Not run by the EU. Powered by PleromaBot, Nitter and PrivacyDev.net.